Every 10-Q that Guided Thera (GTHP) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow GTHP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GTHP filings page.
Guided Therapeutics, Inc. reported interim 2026 results that highlight severe liquidity pressure and continued losses. For the three and six months ended June 30, 2026, sales of devices and disposables were $0, down from $117 thousand in each comparable 2025 period. Operating expenses fell, but the company still posted a six‑month net loss attributable to common stockholders of $1,617 thousand versus $1,319 thousand a year earlier.
Cash and cash equivalents were only $12 thousand at June 30, 2026, with a working capital deficit of about $5.6 million, total liabilities of $6.96 million, and stockholders’ deficit of $5.76 million. Management states that these conditions raise substantial doubt about the ability to continue as a going concern. Net cash used in operating activities increased to $936 thousand from $500 thousand.
The company raised liquidity mainly through equity-linked financing, receiving $980 thousand from warrant exercises and $295 thousand from new notes in the first half of 2026, and converted several series of preferred stock and a convertible note into common shares. The business remains focused on commercialization of the LuViva cervical cancer detection device and on securing FDA and China NMPA approvals, while acknowledging significant industry, regulatory, and geopolitical risks.
Guided Therapeutics, Inc. reported no product sales for the quarter ended March 31, 2026 and a net loss of $500,000, widening to a net loss attributable to common stockholders of $1.013 million after a deemed dividend and preferred dividends.
Cash rose to $369,000 from $63,000 at year-end, mainly from $980,000 of warrant exercises and new notes, but operating activities used $617,000 of cash. The company ended the quarter with a working capital deficit of about $5.1 million, stockholders’ deficit of $5.176 million, and an accumulated deficit of approximately $158.0 million.
Management states these conditions raise substantial doubt about the company’s ability to continue as a going concern and indicates it must raise additional capital to fund operations and support U.S. FDA and China NMPA approval efforts for its LuViva cervical cancer detection device.
Guided Therapeutics (GTHP) reported Q3 2025 results. Sales of devices and disposables were $60 thousand with gross profit of $35 thousand, while operating expenses reached $520 thousand. The company posted a net loss of $742 thousand for the quarter and $1.978 million for the nine months.
Liquidity remains tight with cash and cash equivalents of $87 thousand and total assets of $903 thousand against total liabilities of $6.549 million. Stockholders’ deficit was $5.646 million. The company disclosed a going concern uncertainty, citing a working capital deficit of about $5.7 million and ongoing operating losses.
To fund operations year-to-date, GTHP raised $260 thousand via private placements and $623 thousand in notes (including related parties), and issued 18.47 million shares from conversions, financing, and interest/dividends paid in stock. Deferred revenue stood at $689 thousand, short-term convertible debt in default was $1.130 million, and 83,599,156 common shares were outstanding as of November 10, 2025.